Inloggad som:

Keynote-B21, GOG.3053

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

Keynote-B21, GOG.3053
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE-B21 / ENGOT-en11 / GOG-3053).
PLACEHOLDER
Randomisering mellan tillägg av Pembrolizumab/placeo i kombination med kurativ adjuvant behandling
Mer information om studien för vårdgivare
Behandling
Fas 3
Kurativ
Företag

Studien ändrades senast av: studyjohanna (2021-09-11)

Tillbaka till listan